Analysts Set Liquidia Co. (NASDAQ:LQDA) Price Target at $24.00

Shares of Liquidia Co. (NASDAQ:LQDA - Get Free Report) have received an average recommendation of "Moderate Buy" from the ten ratings firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, six have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $24.00.

A number of equities analysts have commented on LQDA shares. HC Wainwright reiterated a "buy" rating and issued a $29.00 price objective on shares of Liquidia in a report on Thursday, November 14th. Lifesci Capital initiated coverage on Liquidia in a research note on Thursday, October 3rd. They issued an "outperform" rating and a $30.00 price target on the stock. Needham & Company LLC restated a "buy" rating and set a $19.00 price objective on shares of Liquidia in a research note on Thursday, November 14th. Raymond James upgraded Liquidia from an "outperform" rating to a "strong-buy" rating in a research note on Monday, August 19th. Finally, Scotiabank started coverage on shares of Liquidia in a report on Wednesday, October 16th. They issued a "sector outperform" rating and a $30.00 price target on the stock.

Insiders Place Their Bets

In related news, insider Rajeev Saggar sold 2,260 shares of the firm's stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $11.11, for a total value of $25,108.60. Following the sale, the insider now owns 207,383 shares of the company's stock, valued at approximately $2,304,025.13. This trade represents a 1.08 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Roger Jeffs sold 8,053 shares of the business's stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $11.11, for a total value of $89,468.83. Following the transaction, the chief executive officer now owns 812,193 shares of the company's stock, valued at $9,023,464.23. This represents a 0.98 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 22,007 shares of company stock valued at $245,780. Company insiders own 30.10% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Whitcomb & Hess Inc. increased its stake in shares of Liquidia by 10.2% in the third quarter. Whitcomb & Hess Inc. now owns 11,599 shares of the company's stock valued at $116,000 after purchasing an additional 1,074 shares during the period. Arizona State Retirement System increased its position in Liquidia by 10.7% in the 2nd quarter. Arizona State Retirement System now owns 13,842 shares of the company's stock valued at $166,000 after acquiring an additional 1,341 shares during the period. Quest Partners LLC bought a new stake in Liquidia during the 2nd quarter valued at $27,000. Profund Advisors LLC raised its stake in Liquidia by 31.6% during the 2nd quarter. Profund Advisors LLC now owns 14,434 shares of the company's stock valued at $173,000 after acquiring an additional 3,466 shares in the last quarter. Finally, DMC Group LLC boosted its position in Liquidia by 36.7% during the 3rd quarter. DMC Group LLC now owns 13,883 shares of the company's stock worth $139,000 after acquiring an additional 3,725 shares during the period. 64.54% of the stock is owned by institutional investors and hedge funds.

Liquidia Stock Up 2.5 %

Shares of NASDAQ LQDA traded up $0.28 during trading on Tuesday, reaching $11.31. 393,412 shares of the stock were exchanged, compared to its average volume of 966,823. The company has a market capitalization of $957.24 million, a price-to-earnings ratio of -6.82 and a beta of 0.22. The business's 50-day moving average price is $10.93 and its 200 day moving average price is $11.22. Liquidia has a twelve month low of $7.34 and a twelve month high of $16.99.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).